CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors. The Munich-based biotech has raised €50 million...

The SARS-CoV-2 protease is the top target for small molecule COVID-19 candidates developed with a coronavirus infection as their original indication, of which only a handful have entered the clinic. Out of the 281 small molecule...

With more than $1 billion in upfront money via its biggest deal yet, Denali now has enough firepower to bring its lead program into late-stage testing and validate its CNS delivery technology in the clinic....

BioGeneration Ventures is the latest in a string of European early-stage VCs raising upsized funds that give them the ability to commit more capital to portfolio companies and retain larger stakes longer. The firm also...

Epidarex’s latest fund will give the trans-Atlantic firm the ability to retain larger stakes later into the life cycle of portfolio companies. The fund also marks the first life sciences cornerstone investment from the British...

Prism has closed a deal with its second large pharma partner, agreeing to collaborate with Boehringer to discover multiple compounds using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed....

Kurma Partners is the latest European life sciences VC to raise a record fund. The French VC announced the final close of Kurma Biofund III at €160 million ($173.4 million), nearly three times the size...

Beijing antibody play Mabworks raises $160M Mabworks Biotech Co. Ltd. raised RMB1.1 billion ($160 million) in series C1 and C2 rounds to support development and commercialization of its antibody pipeline for various cancers, autoimmune, metabolic...

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing...

LSP has formally closed its sixth fund at $600 million, the largest ever for a European life sciences fund. The firm joins a growing number of European VCs that have announced record fund-raisings in recent...